Description: Ceapro Inc. is a Canada-based growth-stage biotechnology company. The Company's primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human and animal health industries using technology, natural and renewable resources. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides and lupin peptides, which are marketed to the personal care, cosmetic, medical and animal health industries, and Veterinary therapeutic products, including an oat shampoo, an ear cleanser and a dermal complex/conditioner, which are manufactured and marketed to veterinarians in Japan and Asia. Its other products and technologies are in the research and development or pre-commercial stage, which include a potential platform using its beta glucan formulations, and CeaProve, a diabetes test meal to screen pre-diabetes.
Home Page: www.ceapro.com
CZO Technical Analysis
7824 – 51 Avenue NW
Edmonton,
AB
T6E 6W2
Canada
Phone:
780 421 4555
Officers
| Name | Title |
|---|---|
| Mr. Gilles R. Gagnon ICD.D, M.B.A., M.Sc., MBA | CEO, Pres & Director |
| Ms. Stacy Prefontaine CPA, CA | CFO & Corp. Sec. |
| Dr. Bernhard Seifried | Sr. Director of Research & Technology |
| Ms. Sigrun Watson | Chief Revenue Officer |
Exchange: V
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 9.1429 |
| Price-to-Book MRQ: | 1.5955 |
| Price-to-Sales TTM: | 2.5008 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |